Sign In
Buy ANAB
$53.36
-1.68 (-3.05%)
At Close: Jul 31, 2026
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
08:52am, Friday, 21'st Nov 2025
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a par
GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties
08:48am, Friday, 21'st Nov 2025
GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.
GSK, AnaptysBio Sue Each Other Over Cancer Drug License
06:14am, Friday, 21'st Nov 2025
The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.
Anaptys Announces $100 Million Stock Repurchase Plan
04:00am, Friday, 21'st Nov 2025
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its
Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary
03:50am, Friday, 21'st Nov 2025
SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a
GSK unit sues AnaptysBio in row over Jemperli rights
02:36am, Friday, 21'st Nov 2025
GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US subsidiary Tesaro sue AnaptysBio in the Delaware Court of Chancery. Tesaro i
AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement
07:30am, Thursday, 13'th Nov 2025
AnaptysBio receives a "Hold" rating after discontinuing rosnilimab for ulcerative colitis, saving $10 million but maintaining focus on rheumatoid arthritis. ANAB plans to advance rosnilimab for RA, wi
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study
12:30pm, Monday, 10'th Nov 2025
AnaptysBio Inc. (NASDAQ:ANAB) on Monday released data from the Phase 2 trial of rosnilimab for moderate-to-severe ulcerative colitis.
Rosnilimab was safe and well tolerated with similar adverse event rates vs. placebo Observed expected pharmacology, including ~90% depletion of pathogenic T cells, however lack of adequate efficacy at
AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates
06:50pm, Tuesday, 04'th Nov 2025
AnaptysBio, Inc. (ANAB) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $1.06 per share. This compares to a loss of $1.14 per share a year ago.
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
04:15pm, Tuesday, 04'th Nov 2025
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis o
Anaptys Announces Participation in November Investor Conferences
04:15pm, Tuesday, 04'th Nov 2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dani
Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation
09:15am, Wednesday, 29'th Oct 2025
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-brea
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:01am, Tuesday, 28'th Oct 2025
AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AnaptysBio, Inc. - Special Call
05:37am, Wednesday, 15'th Oct 2025
AnaptysBio, Inc. - Special Call Company Participants Daniel Faga - President, CEO & Director Martin Dahl - Senior Vice President of Research John Kwon Paul Lizzul - Chief Medical Officer Conference Ca
